- Home
- SNTG vs CANF Comparison
SNTG vs CANF Comparison
Compare SNTG & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SNTG | CANF |
|---|---|---|
| Founded | 2009 | 1994 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7M | 6.0M |
| IPO Year | 2020 | 2011 |
Fundamental Metrics
Financial Performance| Metric | SNTG | CANF |
|---|---|---|
| Price | $2.11 | $3.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | 5.2K | ★ 1.8M |
| Earning Date | 05-13-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $2,715,455.50 |
| Revenue Next Year | N/A | $101.06 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.60 | $0.17 |
| 52 Week High | $12.70 | $10.40 |
Technical Indicators
Market Signals| Indicator | SNTG | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 49.91 | 49.85 |
| Support Level | $1.86 | $2.91 |
| Resistance Level | $2.43 | $3.42 |
| Average True Range (ATR) | 0.08 | 0.44 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 68.75 | 16.87 |
Price Performance
Historical ComparisonAbout SNTG Sentage Holdings Inc.
Sentage Holdings Inc is a financial service provider. The company offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.